登录

Biotechnology Company Matridx Completes ¥100M Pre-A Round of Financing

作者: Mailman 2020-03-20 12:36
杰毅生物
http://www.matridx.com/
企业数据由 动脉橙 提供支持
体外分子诊断试剂、医疗器械研发商 | C+轮 | 运营中
中国-浙江
2024-02-01
融资金额:数亿人民币
余杭国投集团
查看

According to iivd.net, Matridx, a Hangzhou-based biotechnology company, has announced the completion of its Pre-A Round of about 100 million yuan, with participation from Proxima Ventures, Puhua Capital and other investors focusing on In vitro diagnosis industry. The funds raised will be used for the registration and certification of related equipment and kits of mNGS (metagenomic Next-Generation Sequencing) for metagenomics pathogen detection, and the construction of the service network. 


Matridx was co-founded by Dr. Wang Jun, one of the founding team members of Berry Genomics and Mr. Zhong Jie, the original partners of the Zhejiang Grand Health Industry Equity Investment Fund. As a technology platform based on NGS (Next-Generation Sequencing) and gene editing by CRISPR(Clustered Regularly Interspaced Short Palindromic Repeats) /Cas (CRISPR-associated), Matridx is committed to the innovation of infectious disease testing. 


Matridx is a strategic partner of Alibaba Cloud for AI applications in infectious diseases and the only Chinese firm providing the automatic mNGS detection solution.


Dr. Wang Jun, CEO of Matridx, said, "Currently, our mNGS products have been used in the main battlefield of coronavirus in China, and we are working with the first-line anti-epidemic medical staff to save the lives of more patients. We will also cooperate with qualified ICL (Independent Clinical Laboratories) to promote the application of mNGS."


>>>>

About Proxima Ventures


Proxima Ventures focuses on the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential. They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Proxima Ventures has built 5 transform centers to build and grow healthcare ventures. It has Invested in 23 companies with multiple solutions to patients and been working hard on 36 diseases.


>>>>

About Puhua Capital


Puhua Capital is an equity investment firm that focuses on the early and middle project. The company provides the required resources and management experience for the invested enterprise, investing funds and more resources and wisdom. Puhua Capital has invested nearly 300 excellent start-ups.

相关赛道 IVD
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

FireGen Closes ¥10M Series A+ Round of Financing, Developing Nucleic Acid Detection Devices for Rapid Diagnosis

AcornMed Closes on ¥100M Series A Round of Financing

Targene Biotech Raises ¥100M in Series A Financing, Focusing on Early Diagnosis of Tumor

Anngeen Technologies Snags¥100M in Series B Round

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Yizhun Intelligent Closes on ¥100 million Series B Funding Round

2020-03-20
下一篇

Remegen Snares $100M in A New Funding Round

2020-03-20